Constellation Brands Reschedules Q3 Financial Results Release To January 10, 2025
TikTok's Growing Advertising Base
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
Constellation Brands Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Reported Wednesday, HUTCHMED Divests 45% Stake In Shanghai Hutchison Pharmaceuticals For $608M To Focus On Core R&D And Innovative Oncology Therapies
Reported Wednesday, HUTCHMED And AstraZeneca's ORPATHYS-TAGRISSO Therapy Advances In China With Priority NDA Status For MET-Amplified Lung Cancer